Literature DB >> 18095846

Characterization of nanoparticles for therapeutics.

Jennifer B Hall1, Marina A Dobrovolskaia, Anil K Patri, Scott E McNeil.   

Abstract

Nanotechnology offers many advantages to traditional drug design, delivery and medical diagnostics; however, nanomedicines present considerable challenges for preclinical development. Nanoparticle constructs intended for medical applications consist of a wide variety of materials, and their small size, unique physicochemical properties and biological activity often require modification of standard characterization techniques. A rational characterization strategy for nanomedicines includes physicochemical characterization, sterility and pyrogenicity assessment, biodistribution (absorption, distribution, metabolism and excretion [ADME]) and toxicity characterization, which includes both in vitro tests and in vivo animal studies. Here, we highlight progress for a few methods that are uniquely useful for nanoparticles or are indicative of their toxicity or efficacy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18095846     DOI: 10.2217/17435889.2.6.789

Source DB:  PubMed          Journal:  Nanomedicine (Lond)        ISSN: 1743-5889            Impact factor:   5.307


  65 in total

Review 1.  Theranostic applications of nanomaterials in cancer: drug delivery, image-guided therapy, and multifunctional platforms.

Authors:  Alicia Fernandez-Fernandez; Romila Manchanda; Anthony J McGoron
Journal:  Appl Biochem Biotechnol       Date:  2011-09-27       Impact factor: 2.926

Review 2.  Conscripts of the infinite armada: systemic cancer therapy using nanomaterials.

Authors:  David A Scheinberg; Carlos H Villa; Freddy E Escorcia; Michael R McDevitt
Journal:  Nat Rev Clin Oncol       Date:  2010-03-30       Impact factor: 66.675

Review 3.  Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution.

Authors:  Marina A Dobrovolskaia; Parag Aggarwal; Jennifer B Hall; Scott E McNeil
Journal:  Mol Pharm       Date:  2008-05-30       Impact factor: 4.939

4.  Molecular simulation of protein-surface interactions: benefits, problems, solutions, and future directions.

Authors:  Robert A Latour
Journal:  Biointerphases       Date:  2008-09       Impact factor: 2.456

Review 5.  The evolving landscape of drug products containing nanomaterials in the United States.

Authors:  Sheetal R D'Mello; Celia N Cruz; Mei-Ling Chen; Mamta Kapoor; Sau L Lee; Katherine M Tyner
Journal:  Nat Nanotechnol       Date:  2017-04-24       Impact factor: 39.213

Review 6.  From design to the clinic: practical guidelines for translating cardiovascular nanomedicine.

Authors:  Iwona Cicha; Cédric Chauvierre; Isabelle Texier; Claudia Cabella; Josbert M Metselaar; János Szebeni; László Dézsi; Christoph Alexiou; François Rouzet; Gert Storm; Erik Stroes; Donald Bruce; Neil MacRitchie; Pasquale Maffia; Didier Letourneur
Journal:  Cardiovasc Res       Date:  2018-11-01       Impact factor: 10.787

7.  Self-associated submicron IgG1 particles for pulmonary delivery: effects of non-ionic surfactants on size, shape, stability, and aerosol performance.

Authors:  Asha R Srinivasan; Sunday A Shoyele
Journal:  AAPS PharmSciTech       Date:  2012-12-20       Impact factor: 3.246

8.  Odyssey of a cancer nanoparticle: from injection site to site of action.

Authors:  Joseph W Nichols; You Han Bae
Journal:  Nano Today       Date:  2012-12-01       Impact factor: 20.722

Review 9.  Coaxial electrospray of microparticles and nanoparticles for biomedical applications.

Authors:  Leilei Zhang; Jiwei Huang; Ting Si; Ronald X Xu
Journal:  Expert Rev Med Devices       Date:  2012-11       Impact factor: 3.166

10.  Imaging the distribution of individual platinum-based anticancer drug molecules attached to single-wall carbon nanotubes.

Authors:  Ashwin A Bhirde; Alioscka A Sousa; Vyomesh Patel; Afrouz A Azari; J Silvio Gutkind; Richard D Leapman; James F Rusling
Journal:  Nanomedicine (Lond)       Date:  2009-10       Impact factor: 5.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.